Innovent Biologics Group (HKEX: 01801), a biopharmaceutical company that develops, manufactures and commercialises high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced on Thursday that it has dosed its first patient with moderate-to-severe plaque psoriasis in a phase two clinical trial (clinicaltrials.gov, NCT05003531) of recombinant anti-interleukin 23p19 subunit antibody injection (R & D code: IBI112) in China.

The study is a multicentre, randomised, double-blind, parallel, placebo-controlled Phase two clinical trial, assessing the efficacy and safety of IBI112 at different doses administered subcutaneously to treat moderate-to-severe plaque psoriasis. The main aim of the study is to assess the efficacy of subcutaneous injection of IBI112 at different doses in Chinese patients with moderate-to-severe plaque psoriasis.

The product is a monoclonal antibody independently produced by the company, with independent intellectual property rights.